Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TRVI
TREVI THERAPEUTICS, INC.
NASDAQ
$16.79
▼ DOWN 6.51% (-1.17)

KEY STATISTICS

Market Cap$2.38 B
52w High$20.22
52w Low$6.93
Dividend Yield—
Frequency—
P/E-49.38
Volume1.97M
Shares Out.141.98M

COMPANY

LEADERSHIP

Jennifer L. Good
CHIEF EXECUTIVE
Jennifer L. Good

COMPENSATION 2026

Salary$622,382
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$10,500
Total$3,944,892

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 7, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
34

PRICE TARGET

Target High$40.00
Target Low$23.00
Target Median$27.50
Target Consensus$29.67

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$16.79 ▼ DOWN 6.51% (−$1.17)
$16.80$17.20$17.609:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM16.79

About Trevi Therapeutics, Inc.

https://www.trevitherapeutics.com ↗

Trevi Therapeutics, a clinical-stage biopharmaceutical company in New Haven, develops Haduvio, an oral nalbuphine formulation in phase IIb/III trials for chronic pruritus and cough, with licensing agreements including Endo Pharmaceuticals.

INDUSTRY

Biotechnology

A PRODUCT TREVI THERAPEUTICS, INC. IS KNOWN FOR

Haduvio (nalbuphine ER)
Haduvio (nalbuphine ER)

Haduvio, Trevi Therapeutics' sole investigational oral extended-release tablet, is in clinical trials for treating chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.

COMPETITORS

COMPETITOR
GSK COMPARE
MIRM COMPARE
MRK COMPARE
VNDA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
107
LISTED HERE
17
RANKED BY POSITION SIZE
VTI
0.00% · 4.1M
IWM
0.06% · 2.7M
XPH
1.90% · 622.3K
SCHA
0.04% · 563.4K
LFSC
2.61% · 196.7K
DWAS
0.70% · 168.2K
XRSU.L
0.06% · 98.0K
FESM
0.03% · 93.2K
OP
OPTZ
0.32% · 62.6K
RSSL
0.06% · 51.0K
GSSC
0.06% · 34.6K
PILL
1.28% · 17.5K
FSML
0.10% · 8.3K
BIB
0.08% · 5.1K
TILT
0.00% · 3.3K
USFMDN.MX
0.00% · 496
KBFR
0.06% · 418

INSTITUTIONAL OWNERSHIP

SHARES OWNED
64.83%
HOLDERS
262
TOP 12 OF 262 · RANKED BY POSITION SIZE
Nea Management Company, LLC
13.2M sh · $246.59M
Fmr LLC
12.6M sh · $234.3M
Blackrock, Inc.
11.2M sh · $208.04M
Frazier Life Sciences Management, L.P.
10.3M sh · $93.87M
Rubric Capital Management LP
8.5M sh · $78.07M
Vanguard Group Inc
6.4M sh · $80.56M
Wellington Management Group Llp
5.7M sh · $106.02M
Viking Global Investors LP
5.1M sh · $46.93M
Vivo Capital, LLC
5.1M sh · $95.02M
Marshall Wace, Llp
4.8M sh · $44.3M
Tpg Group Holdings (Sbs) Advisors, Inc.
4.8M sh · $6.75M
Morgan Stanley
4.3M sh · $39.36M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Mathers Edward T
Purchase · 35.0K shares
2026-06-03
★
DIRECTOR
Colangelo Dominick
Purchase · 35.0K shares
2026-06-03
★
DIRECTOR
Meeker David P
Purchase · 35.0K shares
2026-06-03
★
DIRECTOR
VANLENT ANNE
Purchase · 35.0K shares
2026-06-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OUTPERFORM 3
OVERWEIGHT 2
12 GRADES IN THE LAST 12 MONTHS
Jones Trading BUY Oppenheimer OUTPERFORM Cantor Fitzgerald OVERWEIGHT BMO Capital OUTPERFORM HC Wainwright & Co. BUY B. Riley Securities BUY Needham BUY D. Boral Capital BUY

SECTORS PEERS

PEERPRICE
PGEN$6.95COMPARE
ZYME$28.27COMPARE
ZBIO$31.27COMPARE
NVAX$9.26COMPARE
ORIC$13.24COMPARE
WVE$5.04COMPARE
ARDX$3.81COMPARE
UPB$6.69COMPARE